Please use this identifier to cite or link to this item: https://hdl.handle.net/2440/9870
Citations
Scopus Web of ScienceĀ® Altmetric
?
?
Type: Journal article
Title: Efficacy and safety of high-dose lisinopril in chronic heart failure patients at high cardiovascular risk, including those with diabetes mellitus
Author: Ryden, L.
Armstrong, P.
Cleland, J.
Horowitz, J.
Massie, B.
Packer, M.
Poole-Wilson, P.
Citation: European Heart Journal, 2000; 21(23):1967-1978
Publisher: W B Saunders Co Ltd
Issue Date: 2000
ISSN: 0195-668X
1522-9645
Abstract: <h4>Aims</h4>An analysis was designed to determine whether chronic heart failure patients at high cardiovascular risk benefited to the same extent from high-dose lisinopril as the whole ATLAS population.<h4>Methods and results</h4>A retrospective analysis was performed on high-risk heart failure patients in the Assessment of Treatment with Lisinopril And Survival (ATLAS) trial (total number of patients 3164) comparing highdose (32.5-35 mg. day(-1)) vs low-dose (2.5-5 mg. day(-1)) lisinopril for a median of 46 months. These high-risk patients included those with hypotension, hyponatraemia, compromised renal function, the elderly and patients with diabetes mellitus at baseline. In the whole study population, high-dose lisinopril led to a trend in risk reduction of all-cause mortality (primary end-point P=0.128) and a significant risk reduction in all-cause mortality plus hospitalization (principal secondary end-point P=0.002). Subgroup analyses were performed for these end-points. There were no consistent interactions between age, baseline sodium, creatinine or potassium values, and treatment effect. Diabetics showed a beneficial response to high-dose therapy that was at least as good as that in non-diabetics. The underlying higher morbidity/mortality rates in diabetics mean that high-dose lisinopril has potential for a larger absolute clinical impact in these patients.<h4>Conclusion</h4>Long-term high-dose lisinopril was as effective and well-tolerated in high-risk patients, including those with diabetes mellitus, as for the ATLAS study population as a whole.
Keywords: Humans
Diabetes Complications
Chronic Disease
Lisinopril
Angiotensin-Converting Enzyme Inhibitors
Hospitalization
Drug Administration Schedule
Survival Analysis
Retrospective Studies
Databases, Factual
Aged
Aged, 80 and over
Middle Aged
New York
Female
Male
Heart Failure
Randomized Controlled Trials as Topic
DOI: 10.1053/euhj.2000.2311
Appears in Collections:Aurora harvest 4
Medicine publications

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.